

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
なし							

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
1. Iwata H, Naito Y , Hattori M, Yoshimura A, Yonemori K, Aizawa M, Mori Y, Yoshimitsu J, Umeyama Y, Mukohara T.	Safety and pharmacokinetics of vepdegestrant in Japanese patients with ER+ advanced breast cancer: a phase 1 study.	Int J Clin Oncol.	30(1)	72-82	2025
2. Bando H, Naito Y , Yamada T, Fujisawa T, Imai M , Sakamoto Y, Saigusa Y, Yamamoto K, Tomioka Y, Takeshita N, Sunami K, Futamura M, Notake C, Aoki S, Okano K, Yoshino T.	A prospective study comparing highly qualified Molecular Tumor Boards with AI-powered software as a medical device.	Int J Clin Oncol.	30(2)	172-179	2025
3. Yamashita T, Saji S, Takano T, Naito Y , Tsuruneizumi M, Yoshimura A, Takahashi M, Tsurutani J, Iwatani T, Kitada M, Tada H, Mori N, Higuchi T, Iwasasa T, Araki K, Koizumi K, Hasegawa H, Uchida Y, Morita S, Masuda N.	Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.	J Clin Oncol.	43 (11)	1302-1313	2025

4.Kitadai R, Yazaki S, Kuchiba A, Yamanaka T, Shiino S, Yamauchi C, Harano K, Saito M, Hirotsu Y, Aiba H, Yoshida T, Hamamoto R, Shimizu C, Shimomura A, Kojima Y, Shimoi T, Momozawa Y, Sudo K, Yoshida M, Sunami K, Hori M, Katano da K, Shimada Y, Yamashita Y, Kogawa T, Murata T, Fujiwara S, Miyagi Y, Nakagomi H, Tachibana K, Omata M, Ohta ke T, Suto A, Onishi T, Naito Y , Yamashita T, Yonemori K, Kohno T, Shirai shi K.	Germline Pathogenic Variants and Clinical Outcomes in Asian Patients With Breast Cancer.	Cancer Sci.	116(4)	1048-1058	2025
--	--	-------------	--------	-----------	------

5. Fujisawa T, Nakamura Y, Bagendo H, Morizane C, Ikeda M, Nonomura N, Matsubara N, Iwata H, Naito Y , Okano S, Aoki D, Harano K, Yamazaki N, Namikawa K, Ueno M, Kadowaki S, Oki E, Kato K, Komatsu Y, Satoh T, Esaki T, Denda T, Hamaguchi T, Yamazaki K, Matsuhashi N, Yasui H, Satake H, Nishina T, Takahashi N, Goto M, Sunakawa Y, Kato T, Otsuka T, Abutani H, Tukachinsky H, Lee JK, Oxnard GR, Kuramoto N, Horasawa S, Sakamoto Y, Taniguchi H, Yoshino T.	Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: S-CRUM-Japan MONSIEUR-SCREEN-1 Study.	JCO Precis Oncol.		e2400283	2025
6. Funasaka C, Kogawa T, Sakamoto N, Kusuhara S, Nakao T, Nakajima H, Kondoh C, Hanano K, Matsubara N, Hosono A, Naito Y , Shimokawa M, Watanuki R, Yamashita Y, Yamauchi C, Onishi T, Ishii G, Mukohara T.	The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer.	Cancer Treatment Res Commun	44	100941	2025
7. Naito Y , Iwagami S, Doi T, Takahashi T, Kurokawa Y.	Pimipib in patients with advanced gastrointestinal stromal tumors in Japan: an expanded access program.	Int J Clin Oncol.	30(5)	935-943	

8. Yazaki S, Hori M, Aiba H, Momozawa Y, Yoshida M, Shiino S, Harano K, Yamauchi C, Yamanaka T, Miwa M, Matsuda K, Kawai Y, Kobayashi-Kato M, Kitagawa M, Saito M, Nakagomi H, Tachibana K, Sakamoto I, Takahashi K, Asami Y, Katanoda K, Kuchiba A, Yoshida H, Ishikawa M, Shimoi T, Sudo K, Shimizu C, Shimomura A, Murata T, Yamashita Y, Kogawa T, Fujiwara S, Saji H, Kato H, Miyagi E, Iwasaki Y, Aoi T, Takata S, Ogasawara A, Ohtake T, Fujimori K, Hirotsu Y, Nagashima M, Komatsu M, Hamamoto R, Hirata M, Yoshida T, Honda T, Hiranuma K, Matsuda M, Shimada Y, Sunami K, Noiri E, Omae Y, Matsumoto K, Okamoto A, Omata M, Watanabe T, Miyagi Y, Murakami Y, Tokunaga K, Hasegawa K, Kato T, Onishi T, Yamashita T, Naito Y, Suto A, Yonemori K, Kohno T, Shiraisihi K; BioBank Japan Project; NCBN Controls WGS Consortium.	Impact of germline variants on breast and ovarian cancer risk in Japanese women: an original cohort study and meta-analysis.	EBioMedicine	116	105758	2025
--	--	--------------	-----	--------	------

9. Yap TA, Goldman JW, Vinayak S, Tomova A, Hamilton E, Naito Y , Giordano A, Bondarenko I, Yamashita T, Zhou L, Moreau A, Neumann H, Tougias J, Liu F, Park J, Delioukina M, Jhaveri K.	First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer.	Clin Cancer Res	31(14)	2899-290	2025
10. Hirano H, Naito Y , Nishida T, Higashi T, Satake T, Morizane C, Kawai A.	Epidemiologic Features and Age-Related Differences in Management among Patients with Gastrointestinal Stromal Tumors in Japan: A National Cancer Registry Study.	Cancer Res Commun.	5(7)	1235-1242.	2025
11. Funasaka C, Naito Y , Kubota H, Ishiguro Y, Fuse N, Wakabayashi M, Sato A, Yuda J, Ishii G, Suzuki T, Takenouchi K, Nakatsura T, Morita K, Inada Y, Tanaka M, Nakazawa Y, Yagyu S, Doi T.	Trial in progress: phase I study of non-viral gene-modified CAR-T cell therapy for malignant solid tumors expressing EPHB4 receptor (CARTiEr).	Front Oncol.	15	1633324	2025
12. Kurokawa Y, Honma Y, Sawaki A, Naito Y , Iwagami S, Komatsu Y, Takahashi T, Nishida T, Doi T.	Pimlitespib for advanced gastrointestinal stromal tumor: a plain language summary of the CHAPTER-GIST-301 study.	Future Oncol	21(19)	2401-2413	2025
13. Fujisawa Y, Yoshioka Y, Yoshino K, Fujimura T, Naito Y , Masuzawa M, Oashi K, Nakano E, Kato H, Muto Y, Koga H, Miyagaki T, Uchi H, Nakamura Y, Asagoe K.	Secondary Publication of Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Cutaneous Angiosarcoma 2025.	J Dermatol.	52(10)	e859-e875	2025

14. Yazaki S, Kitadai R, Momotazawa Y, Yoshida T, Yamanaka T, Shiino S, Yamamachi C, Harano K, Saito M, Hirotsu Y, Aiba H, Hamamoto R, Shimizu C, Shimomura A, Shimo T, Sudo K, Yoshida M, Sunami K, Shiraishi Y, Kuchiba A, Hori M, Katanoda K, Takata S, Ogawa A, Torasawa M, Mochizuki A, Shimada Y, Hirayama K, Fujii E, Hirata M, Yamashita Y, Kogawa T, Murata T, Fujiwara S, Miyagi Y, Nakagomi H, Tachibana K, Matsuda K, Murakami Y, Tokunaga K, Kawai Y; NCBN Controls WG; S Consortium; Project B, Omata M, Ohtake T, Suto A, Onishi T, Naito Y , Yamashita T, Yonemori K, Kohno T, Shiraishi K.	Germline variants of the POLH and RAD51 genes are candidate variants associated with risk of hormone receptor-negative young-onset breast cancer.	NPJ Breast Cancer.	11(1)	133	2025
15. Hayakawa M, Nakajima H, Harano K, Watanabe S, Tsuchimochi S, Uematsu M, Fukuda M, Funasaka C, Kondoh C, Matsubara N, Naito Y , Hironaka A, Wakabayashi M, Takahashi K, Tanabe H, Mukohara T.	Impact of platinum-free interval and bevacizumab on second-line chemotherapy following progression on first-line PARP inhibitor maintenance in advanced ovarian cancer: A retrospective cohort study.	Gynecol Oncol.	204	70-78	2026

16. Shimomura A, Kogawa T, Matsumoto K, Watanabe J, Watanabe K, Nakatani T, Shien T, Iwasa T, Paudyal S, Huynh D, Shao J, Kwak J, Iwahori Y, Naito Y , Iwata H.	Sacituzumab govitecan in Japanese patients with HR+/HER2- metastatic breast cancer: primary results from the phase II ASCENT-J02 study.	Jpn J Clin Oncol.		hyag043	2026
17. Shien T, Ishitobi M, Sakaki K, Tanaka K, Shimomura A, Tsukioki T, Sagara Y, Kimura Y, Terata K, Ishihara T, Yasojima H, Ono M, Goda K, Naito Y , Fujisawa T, Hara F, Ogawa G, Fukuda H, Iwata H; Breast Cancer Study Group of Japan Clinical Oncology Group (JCOG), Japan.	Efficacy and prognostic predictors of primary systemic therapy for de novo Stage I/II breast cancer. Exploratory analysis of JCOG1017 PRIM-BC.	Breast Cancer	33(2)	396-406	2026
18. Shigematsu H, Fujisawa T, Hara F, Iwata H, Ishiba T, Ozaki Y, Sakai T, Sagara Y, Shimomura A, Sudo K, Terata K, Naito Y , Nozawa K, Sasaki K, Mitome N, Sadachi R, Shibata T, Shien T.	Clinical complete response and predictive factors in HER2-positive early breast cancer treated with neoadjuvant chemotherapy aimed at omission of surgery: an exploratory analysis of the JCOG1806 trial.	Int J Clin Oncol.	31(3)	528-536	2026

19. Yamaguchi M, Higuchi D, Yoshida H, Fujii E, Kato MK, Hiranuma K, Asami Y, Ono H, Koyama T , Koyama T, Koyama M, Hamamoto R, Matsumoto K, Sekizawa A, Terao Y, Itakura A, Kohno T, Kato T, Makinoshima H, Ishikawa M, Shiraishi K.	Metabolomic and transcriptomic analyses identify metabolic alterations and immune suppression in ovarian cancer.	Sci Rep.	16	7429	2026
20. Ogura N, Hirano H, Shiraishi K, Fujii H, Hirose T, Shoji H, Okita N, Takashima A, Koyama T , Yonemori K, Kato K.	Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan.	JCO Precis Oncol.	10	e2500562	2026
21. Murciano-Goroff YR, Holleb EC, Heist RS, Cassier PA, Han JY, Kim SY, Sabari JK, Tosi D, Sacher A, Burns TF, Shimizu T, Reddy Ammakkanavar N, Spira A, Gomez-Roca C, Patnaik A, Cosman R, Bodor JN, Nagasaka M, You AX, McNeely SC, Peter R, Fink A, Chen A, Oxnard GR, Willard MD, Kuboki Y, Koyama T .	Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.	Nat Commun	17	3834	2026
22. Koyama T , Shimizu T, Kontodou S, Katsuya Y, Sudo K, Yoshida T, Yonemori K, Matsumoto K, Yamamoto N.	Tolerability and safety of magrolimab (ONO-7913) in Japanese patients with advanced or metastatic solid tumors: a phase 1, open-label, uncontrolled, dose-escalation study.	BMC Res Notes.	19	203	2026

23. Katsuya Y, Koyama T , Sato J, Okada M, Yamamoto N.	Evolving phase I oncology trials in the precision medicine era: design, outcomes, and geographic access.	ESMO Real World Data Digit Oncol	11	100692	2026
24. Kamio S, Oogura K, Suehara Y, Kitada R, Ikegami M, Sunami K, Koyama T , Yamamoto N, Shimomura S, Kondo H, Takemori T, Osaki S, Kobayashi E, Iwata S, Kohsaka S, Kawai A	Analysis of comprehensive genomic profiling test for Ewing sarcoma in pediatric patients and adults using the nationwide clinical and genomic database in Japan.	Jpn J Clin Oncol.	56(1)	33–39	2026
25. Hamamoto R, Koyama T , Takahashi S, Yasuda T, Kobayashi K, Akagi Y, Kouno N, Suedo K, Hirata M, Sunami K, Kubo T, Katayama H, Takashima A, Taniguchi T, Matsumoto H, Shibaki R, Asada K, Komatsu M, Kaneko S, Yamada M, Horinouchi H, Tanaka K, Goto Y, Kato K, Saito Y, Nakamura K, Yamamoto N.	Implementing generative artificial intelligence in precision oncology: safety, governance, and significance.	J Hematol Oncol.	19	14	2026
26. Uehara Y, Koyama T , Katsuya Y, Sato J, Sudo K, Kondo S, Yoshida T, Shoji H, Shimoi T, Okada M, Yonemori K, Yamamoto N.	Impact of travel costs on disparities in precision oncology clinical trials.	ESMO Real World Data and Digital Oncology	7	100114	2025

27. Sudo K, Nishimura R, Sudo K, Kitadai R, Kawachi A, Ito M, Hoshino M, Kita S, Saito A, Kojima Y, Maet. jima A, Noguchi E, Okuma H S, Koyama T , Shimoi T, Yonemori K.	Treatment and Recommendations for Choosing Treatment in Breast Cancer Patients Who Underwent Next-Generation Sequencing Tests.	Oncology.	103	1128–1137	2025
28. Sanomachi T, Katsuya Y, Nakatsura T, Koyama T .	Next-Generation CAR-T and TCR-T Cell Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends.	Cancers (Basel)	17	1945	2025
29. Liu J, Farrar M, Seymour L, Desai J, Long HH, Ivy P, Koyama T , Cook N, Blagden S, Garralda E, Massard C, Tolcher AW, Adashek JJ, Zhang L, Zhao S, Shen L, Kurzrock R, El-Deiry WS, Subbiah V, Joshua AM.	Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials.	J Clin Oncol	43	6	2025
30. Kuboki Y, Matsubara N, Nakajima H, Fujisawa T, Koyama T , Sato J, Katsuya Y, Kmieciak A, Slade D, Iwata K, Takahashi Y, Nii M, Murayama K, Kawata T, Kawasumi H, Yamamoto N.	Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study.	Invest New Drugs	43	1235–1246	2025
31. Kitadai R, Okuma Y, Shibata T, Kohno T, Koyama T .	Tissue-agnostic target profiles and treatment efficacy in cancer patients: Insights from the C-CAT clinicogenomic repository.	Eur J Cancer	220	115380	2025

32. Katsuya Y, Ikeda M, Koyama T , Sato J, Okada M, Matsubara N, Kondoh C, Mukohara T, Watanabe K, Kotani D, Ogawa Y, Taoka S, Yamamoto N	A Phase I, First-In-Human Study of CB A-1205, an Anti-DLK1 Monoclonal Antibody, in Patients With Advanced Solid Tumors.	Cancer Sci.	116(4)	1012–1022	2025
33. Ishii T, Kohno T, Yugawa T, Suzuki T, Koyama T , Higashi T, Mano H, Okuma Y.	Real-World Comparison of Gene-Matched vs. Non-Gene-Matched Therapy Outcomes Using Integrated Genomic and Clinical Data.	Cancer Sci.	116	2788–2796	2025
34. Higuchi D, Yamaguchi M, Fujii E, Kato M, K, Hiranuma K, Asami Y, Ono H, Koyama T , Komatsu M, Hamamoto R, Terao Y, Matsumoto K, Sekizawa A, Ishikawa M, Kohno T, Yoshida H, Makinoshima H, Shiraishi K, Kato T.	TP53 gene and pathway alterations in gastric-type adenocarcinoma of the cervix.	JNCI Cancer Spectr	9(5)	pkaf082	2025
35. Hamamoto R, Komatsu M, Yamada M, Kobayashi K, Takahashi M, Miyake M, Jinnai S, Koyama T , Kono N, Machino H, Takahashi S, Asada K, Ueda N, Kaneko S.	Current status and future direction of cancer research using artificial intelligence for clinical applications.	Cancer Sci	116	297–307	2025
36. Fukuda A, Mizuno T, Yoshida T, Sunami K, Kubo T, Koyama T , Yonemori K, Okusaka T, Kato K, Ohe Y, Yatabe Y, Yamamoto N.	Upfront liquid biopsy in patients with advanced solid tumors who were not feasible for tissue-based next-generation sequencing.	Jpn J Clin Oncol.	55(7)	720-728	2025

37. Fujii E, Kato MK, Ono H, Yamaguchi M, Higuchi D, Koyama T , Komatsu M, Hamamoto R, Ishikawa M, Kato T, Kohno T, Shiraishi K, Yoshida H.	TP53 Mutations and PD-L1 Amplification in Vulvar Adenocarcinoma of the Intestinal Type: Insights From Whole Exome Sequencing of 2 Cases.	Int J Gynecol Pathol.	6	358-363	2025
38. Burns TF, Ammakkanavar NR, Hollebecq, Lee DH, Koyama T , Cassin PA, Italiano A, Han JY, Singh N, Takeuchi S, Heist RS, Deming D, Spira A, Chu Q, Sacher A, Fujiwara Y, Chisamore MJ, You AX, McCNeely SC, Fink A, Chen A, Oxenard GR, Willard MD, Murciano-Goroff YR, Dragnev KH.	Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.	J Thorac Oncol.	21	4	2025